Holostem Terapie Avanzate

What Holostem Terapie Avanzate does

Holostem Terapie Avanzate S.r.l. is an Italian biotechnology company founded in 2007 as a university spin-off of the University of Modena and Reggio Emilia, headquartered at the Centro di Medicina Rigenerativa "Stefano Ferrari" in Modena. The company develops, manufactures, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell therapy and gene therapy applications. Its commercial product, Holoclar, is an autologous limbal stem cell therapy for the treatment of Limbal Stem Cell Deficiency (LSCD) caused by severe physical or chemical corneal burns; it is the first stem cell-based therapy approved in Europe (conditional authorization 2015, full authorization in EU and UK in 2024). The pipeline includes Hologene 5, a combined cell and gene therapy for Junctional Epidermolysis Bullosa currently in Phase II/III, and GPLSCD01, an FDA Orphan Drug-designated LSCD product targeting the US market.

Holostem's business model is B2B enterprise-style: Holoclar is produced in a single GMP-certified facility in Modena and distributed to a network of approximately 20 authorized treatment centers across 10 European countries (Italy, UK, Germany, Austria, Belgium, Netherlands, Denmark, France, Spain, Poland). Because the autologous graft has a 36-hour shelf life, logistics and direct coordination with hospital pharmacies are central to operations. Pricing is negotiated on a per-patient basis, with treatment costs typically covered by European national healthcare systems. Distribution has historically relied on Chiesi Farmaceutici (which held EU marketing authorization from 2015 until June 2020, when Holostem assumed full lifecycle control) and on partnerships such as Newcastle Hospitals NHS Foundation Trust for UK access.

The company operates with 11–50 employees under the scientific leadership of co-founders Prof. Michele De Luca (Scientific Director) and Prof. Graziella Pellegrini (R&D Director), and CEO Alessandro Padova. In June 2022 the Board of Directors approved a transition to a nonprofit foundation (fondazione) structure, signaling that future ownership and growth will prioritize patient access and research mission over venture-scale commercialization. Strategic support has come from Chiesi Farmaceutici's founding investment, a ~€2.5 million ERC Advanced Grant (2021) for the Holo-GT gene therapy project, and selection as a participant in the European Commission's IPCEI Med4Cure initiative (May 2024).

Name

Holostem Terapie Avanzate

Legal name

Holostem Terapie Avanzate S.r.l.

Website

https://holostem.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Holostem Terapie Avanzate is an Italian biotech developing and manufacturing autologous epithelial stem cell ATMPs, commercially distributing Holoclar (the first EU-approved stem cell therapy, for Limbal Stem Cell Deficiency) to ~20 hospital centers across 10 European countries, with a gene therapy pipeline for Epidermolysis Bullosa.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Regenerative medicine
• Advanced therapy medicinal products
• Autologous cell therapy
• Epithelial stem cells
• Combined cell and gene therapy

Headquarters

HQ city

Modena

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Holoclar Product Sales: Sale of Holoclar, an autologous cell therapy product for limbal stem cell deficiency. The product is distributed directly to authorized treatment centers across European countries. Pricing is negotiated on a per-patient basis given the personalized nature of the therapy.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Holostem develops, manufactures, and distributes Advanced Therapy Medicinal Products (ATMPs) based on autologous epithelial stem cell cultures. Its commercial product Holoclar is an autologous limbal stem cell therapy for corneal surface reconstruction in patients with limbal stem cell deficiency caused by chemical or physical burns. The pipeline includes Hologene 5, a combined cell and gene therapy in Phase II/III for junctional epidermolysis bullosa, and GPLSCD01 with FDA Orphan Drug Designation for the US market.

Product overview

Holostem Terapie Avanzate is a biotech company specializing in regenerative medicine from epithelial stem cells. The company's product portfolio consists of Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell therapy and gene therapy applications. The core commercial product is Holoclar, an autologous stem cell therapy for corneal surface reconstruction approved in the EU and UK. The pipeline includes Hologene 5, a combined cell and gene therapy for Epidermolysis Bullosa in clinical trials, and GPLSCD01 with FDA orphan designation for the US market. The company develops treatments for epithelial tissues including cornea, skin, urethra, oral mucosa, and respiratory epithelia.

Differentiator

Problem solved

Functional benefit

Brands

• Holoclar: Autologous epithelial cell therapy product for limbal stem cell deficiency (LSCD) due to physical or chemical corneal burns. First stem cell-based therapy approved in Europe (2015) and subsequently granted full marketing authorization in EU and UK (2024).
• Hologene 5
• GPLSCD01

Products and services

• Holoclar Advanced Therapy Medicinal Product (ATMP) based on autologous limbal stem cells for corneal surface reconstruction. Treats Limbal Stem Cell Deficiency (LSCD) caused by severe chemical or physical burns to the eye. Manufactured from a 1-2 mm² biopsy of the patient's undamaged limbus, expanded ex vivo into a corneal epithelial sheet containing stem cells for transplantation. Intended for hospital treatment centers and ophthalmology specialty centers across Europe.
• Hologene 5 Combined cell and gene therapy product in Phase II/III clinical trials for the treatment of Junctional Epidermolysis Bullosa (EB), a rare genetic skin disease known as 'butterfly children' disease. Uses transgenic epidermal cultures to deliver functional LAMB3 genes to correct the genetic defect in patient-derived stem cells. Intended for specialized pediatric and dermatology hospitals collaborating in advanced therapy programs.
• GPLSCD01 Experimental drug consisting of autologous ex vivo expanded corneal epithelial cells (same as Holoclar in the EU) designated as an orphan drug by the FDA for treatment of Limbal Stem Cell Deficiency (LSCD) in the United States.

Quantifiable outcome

• Overall success rates of 51-77% in HOLOCORE clinical study, with 60% improvement in LSCD patient population after average 153 months of follow-up
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Fondazione Banca degli Occhi del Veneto (Veneto Eye Bank Foundation)coreStrategic or Co-development Partner · 15 October 2025Strategic partnership to expand access to advanced therapies for ocular diseases. The agreement focuses on strengthening the network of centers administering Holoclar, sharing expertise for medical training and research on stem cells applied to eye treatment. This public-private collaboration demonstrates synergy between research institutions and advanced therapy manufacturers.
• Newcastle Hospitals NHS Foundation TrustcoreChannel Partner/ Reseller/ Distributor · 24 June 2022Partnership enabled Holoclar access for NHS patients across specialist centers in England. The Newcastle pharmacy team worked with Holostem to overcome regulatory and importation barriers for the 36-hour shelf-life cell therapy product, creating a replicable model for NHS access to advanced therapies.
• Northern Alliance Advanced Therapies Treatment CentresupportingImplementation/ SI/ Consulting Partner · 24 June 2022Facilitated partnership between Newcastle Hospitals and Holostem, working to support advanced therapy adoption and ensure patient access to innovative treatments within the NHS system.
• Chiesi FarmaceuticicoreChannel Partner/ Reseller/ Distributor · 20 February 2015Chiesi held European marketing authorization for Holoclar from 2015, with Holostem as manufacturer. In June 2020, Holostem signed agreement for transfer of Holoclar marketing authorization from Chiesi Group to Holostem, enabling the company to manage the complete product lifecycle independently.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Chiesi Farmaceutici: Italian specialty pharmaceutical company that was Holostem's founding strategic investor, original Holoclar marketing authorization holder (2015-2020), and remains a parent/strategic shareholder. Comparable as a broader rare-disease commercial operator with direct operational familiarity of Holostem's epithelial stem cell therapy platform.
• uniQure: European-headquartered gene therapy company with a marketed AAV-based therapy for a rare disease (hemophilia B via Hemgenix partnership). Comparable as a broader rare-disease gene therapy operator with European regulatory footing and an established advanced therapy manufacturing footprint.
• BioMarin Pharmaceutical: Global rare-disease biopharmaceutical company with multiple marketed specialty biologics and a gene therapy franchise (Roctavian for hemophilia A). Comparable as a broad incumbent commercial rare-disease operator with advanced therapy experience relevant to Holostem's scaling and reimbursement journey.
• Vertex Pharmaceuticals: Global biotech with Casgevy, the first FDA-approved CRISPR/Cas9 gene-edited cell therapy (for sickle cell disease and beta thalassemia). Comparable as an established advanced-therapy operator that has set payer and regulatory precedents for autologous gene-edited cell therapies relevant to Holostem's Hologene 5 gene therapy strategy.

Direct peers

• Lineage Cell Therapeutics: US-based clinical-stage cell therapy company developing allogeneic cell transplants for ophthalmology (e.g., OpRegen for macular degeneration) and CNS indications. Directly comparable as a cell-therapy developer focused on rare ocular surface/disease indications using proprietary cell expansion platforms.
• jCyte: Clinical-stage biotech developing jCell, an autologous retinal progenitor cell therapy for retinitis pigmentosa. Directly comparable to Holostem as a developer of autologous cell therapies for rare ophthalmic indications using stem/progenitor cell platforms.
• Spark Therapeutics (Roche): Gene therapy company (acquired by Roche) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65). Directly comparable to Holostem in applying advanced therapy modalities (cell/gene) to rare ophthalmic indications, with established regulatory precedent that informs Holostem's US pathway.
• Castle Creek Biosciences: Late-clinical-stage gene therapy company developing autologous gene-modified cell therapies (including for epidermolysis bullosa). Highly directly comparable as a developer of ex-vivo gene-corrected autologous cell therapies for rare epithelial/skin disease, addressing the same Hologene 5 therapeutic area.
• Mesoblast: Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and rare diseases. Directly comparable as an approved-marketing cell therapy developer using proprietary stem cell expansion technology in specialty/rare indications.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem, an allogeneic stem cell therapy for multiple inflammatory, neurological, and rare indications. Comparable as a peer stem cell therapy platform pursuing late-stage trials in underserved specialty indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/HolostemTA
• YouTubeyoutube.com/channel/UCViGUGmHxtFeLPEFgclvCaA
• Facebookfacebook.com/holostem
• LinkedInlinkedin.com/company/holostem

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Holostem Terapie Avanzate